Clyburn Frank
SEC CIK 1763963 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | Dir | 10.9K | — | — | 3 | 2024-08-05 | 2026-06-18 |
| COR | Cencora | Dir | 1,724 | — | — | 3 | 2024-11-01 | 2026-03-05 |
| IFF | International Flavors & Fragrances | CEO | 1,847 | — | — | 4 | 2023-03-01 | 2024-03-01 |
| MRK | Merck & Co. | EVP, Pres ? Human Health | 136.9K | — | $3.49M | 3 | 2021-10-30 | 2021-11-01 |
Most active insiders at RVMD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | GOLDSMITH MARK A | See Remarks, Dir | — | $56.99M |
| 2 | Kelsey Stephen Michael | See Remarks | — | $22.55M |
| 3 | Cislini Jeff | SVP, GC | — | $15.19M |
| 4 | Kim Lorence H. | Dir | — | $14.97M |
| 5 | Horn Margaret A | COO | — | $10.84M |
| 6 | Mancini Anthony | See Remarks | — | $9.05M |
| 7 | Anders Jack | CFO | — | $7.13M |
| 8 | ANDERSON ELIZABETH M | Dir | — | $1.96M |
| 9 | Patel Sushil | Dir | — | $1.05M |
| 10 | Wei Lin | Chief Medical Off | — | $206.2K |
| 14 | Clyburn Frank | Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-23 17:44 | 2026-06-18 | RVMD | Revolution Medicines, Inc. | Clyburn Frank | Dir | A - Grant | $0.00 | +1,191 | 10.9K | +12% | $0 |
| 2026-03-09 | 2026-03-05 | COR | Cencora | Clyburn Frank | Dir | A - Grant | $359.28 | +557 | 1,724 | +48% | +$200.1K | |
| D | 2025-06-30 | 2025-06-26 | RVMD | Revolution Medicines, Inc. | Clyburn Frank | Dir | A - Grant | $0.00 | +2,806 | 9,738 | +40% | $0 |
| 2025-03-10 | 2025-03-06 | COR | Cencora | Clyburn Frank | Dir | A - Grant | — | +789 | 1,157 | +214% | — | |
| 2024-11-05 | 2024-11-01 | COR | Cencora | Clyburn Frank | Dir | A - Grant | $234.27 | +368 | 368 | New | +$86.2K | |
| D | 2024-08-07 | 2024-08-05 | RVMD | Revolution Medicines, Inc. | Clyburn Frank | Dir | A - Grant | $0.00 | +6,932 | 6,932 | New | $0 |
| D | 2024-03-05 | 2024-03-01 | IFF | International Flavors & Fragrances | Clyburn Frank | CEO | F - Tax | $75.88 | -323 | 1,847 | -15% | -$24.5K |
| D | 2024-03-05 | 2024-03-01 | IFF | International Flavors & Fragrances | Clyburn Frank | CEO | M - OptEx | $0.00 | +1,324 | 2,170 | +157% | $0 |
| D | 2023-03-02 | 2023-03-01 | IFF | International Flavors & Fragrances | Clyburn Frank | CEO | F - Tax | $91.64 | -477 | 846 | -36% | -$43.7K |
| D | 2023-03-02 | 2023-03-01 | IFF | International Flavors & Fragrances | Clyburn Frank | CEO | M - OptEx | $0.00 | +1,323 | 1,323 | New | $0 |
| DM | 2021-11-02 | 2021-10-30+ | MRK | Merck & Co. | Clyburn Frank | EVP, Pres ? Human Health | M - OptEx | $4.93 | +42.1K | 136.9K | +44% | +$207.6K |
| D | 2021-11-02 | 2021-10-30 | MRK | Merck & Co. | Clyburn Frank | EVP, Pres ? Human Health | F - Tax | $88.05 | -1,162 | 97.1K | -1% | -$102.3K |
| D | 2021-11-02 | 2021-11-01 | MRK | Merck & Co. | Clyburn Frank | EVP, Pres ? Human Health | S - Sale+OE | $87.87 | -39.8K | 97.1K | -29% | -$3.49M |
Purchase Sale Sale after option exercise All abbreviations